Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
Shengyuan Luo,Alexi Vasbinder,Jeanne M. Du‐Fay‐de‐Lavallaz,Joanne Michelle D. Gomez,Tisha Suboc,Elizabeth Anderson,Annika Tekumulla,Husam Shadid,Hanna Berlin,Michael Pan,Tariq U. Azam,Ibrahim Khaleel,Kishan Padalia,Chelsea Meloche,Patrick O'Hayer,Tonimarie Catalan,Pennelope Blakely,Christopher Launius,Kingsley‐Michael Amadi,Rodica Pop‐Busui,Sven H. Loosen,Athanasios Chalkias,Frank Tacke,Evangelos J. Giamarellos‐Bourboulis,Izzet Altintas,Jesper Eugen‐Olsen,Kim A. Williams,Annabelle Santos Volgman,Jochen Reiser,Salim S. Hayek,Salim S. Hayek,Pennelope Blakely,Christopher Launius,Hanna Berlin,Kingsley Amadi,Tariq U. Azam,Husam Shadid,Michael Pan,Patrick O’Hayer,Chelsea Meloche,Rafey Feroze,Kishan J. Padalia,Elizabeth Anderson,Danny Perry,Abbas Bitar,Rayan Kaakati,Lili Zhao,Peiyao Zhao,Erinleigh Michaud,Yiyuan Huang,Toniemarie Catalan,Ibrahim Khaleel,Jochen Reiser,Beata Samelko,Alexander Hlepas,Xuexiang Wang,Priya Patel,Jesper Eugen‐Olsen,Izzet Altintas,Jens Tingleff,Marius Stauning,Morten Baltzer Houlind,Mette B. Lindstrøm,Ove Andersen,Hejdi Gamst‐Jensen,Line Jee Hartmann Rasmussen,Christian Rasmussen,Jan O. Nehlin,Thomas Kallemose,Imran Parvaiz,Evangelos J. Giamarellos‐Bourboulis,Maria‐Evangelia Adami,Nicky Solomonidi,Maria Tsilika,Maria Saridaki,Vasileios Lekakis,Sven Loosen,Tom Luedde,Verena Keitel,Athanasios Chalkias,Ioannis Pantazopoulos,Eleni Laou,Anargyros Skoulakis,Frank Tacke,Pinkus Tober‐Lau,Raphael Mohr,Florian Kurth,Leif Erik Sander,Christoph Jochum,Philipp Koehler
DOI: https://doi.org/10.1161/JAHA.122.025198
IF: 6.106
2022-08-05
Journal of the American Heart Association
Abstract:Background Venous thromboembolism (VTE) contributes significantly to COVID‐19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (suPAR) reflect hyperinflammation and are strongly predictive of outcomes in COVID‐19. Whether suPAR levels identify patients with COVID‐19 at risk for VTE is unclear. Methods and Results We leveraged a multinational observational study of patients hospitalized for COVID‐19 with suPAR and D‐dimer levels measured on admission. In 1960 patients (mean age, 58 years; 57% men; 20% Black race), we assessed the association between suPAR and incident VTE (defined as pulmonary embolism or deep vein thrombosis) using logistic regression and Fine‐Gray modeling, accounting for the competing risk of death. VTE occurred in 163 (8%) patients and was associated with higher suPAR and D‐dimer levels. There was a positive association between suPAR and D‐dimer (β=7.34; P =0.002). Adjusted for clinical covariables, including D‐dimer, the odds of VTE were 168% higher comparing the third with first suPAR tertiles (adjusted odds ratio, 2.68 [95% CI, 1.51–4.75]; P <0.001). Findings were consistent when stratified by D‐dimer levels and in survival analysis accounting for death as a competing risk. On the basis of predicted probabilities from random forest, a decision tree found the combined D‐dimer <1 mg/L and suPAR <11 ng/mL cutoffs, identifying 41% of patients with only 3.6% VTE probability. Conclusions Higher suPAR was associated with incident VTE independently of D‐dimer in patients hospitalized for COVID‐19. Combining suPAR and D‐dimer identified patients at low VTE risk. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04818866. Nonstandard Abbreviations and Acronyms ISIC International Study of Inflammation in COVID‐19 suPAR soluble urokinase plasminogen activator receptor uPA urokinase plasminogen activator uPAR urokinase plasminogen activator receptor Clinical Perspective What Is New? This is the first study to evaluate the association between soluble urokinase plasminogen activator receptor (suPAR) and venous thromboembolism (VTE) in the setting of acute viral illness, such as COVID‐19. There was a significant association between suPAR and risk for VTE in COVID‐19 that was independent of plasma D‐dimer level. The subgroup of patients with suPAR <11 ng/mL and D‐dimer <1 mg/L had only a 3.6% probability of incident VTE and accounted for 41% of patients hospitalized for COVID‐19. What Are the Clinical Implications? Characterizing the association between suPAR and VTE risk furthers our understanding of the prognostic role of suPAR, a biomarker with established clinical utility in guiding immunotherapy treatment in COVID‐19. The combined D‐dimer and suPAR diagnostic cutoffs could refine the risk stratification for VTE among patients hospitalized with COVID‐19. Venous thromboembolism (VTE) is a highly prevalent COVID‐19 complication, estimated to occur in as many as 26% of patients hospitalized for the disease. 1 Pulmonary embolism remained prevalent despite certain immunomodulators effective at stalling the progression of respiratory illness. 2 It was the direct cause of death in close to one third of patients with COVID‐19 despite prophylaxis with anticoagulants. 3 Such excessive thromboembolic risk is thought to be attributable to not only critical illness but immunothrombosis, a condition where viral infection induces immune dysregulation and significant vascular inflammation, ultimately resulting in microangiopathy and macroangiopathy. 4 , 5 , 6 D‐dimer is the most commonly used biomarker for VTE but has been shown to be less reliable in COVID‐19. 7 Combining it with markers of immune dysregulation could refine the risk stratification of patients with COVID‐19. The urokinase plasminogen activator (uPA)/urokinase plasminogen acti -Abstract Truncated-
cardiac & cardiovascular systems